unapproved substance comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-09-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516, GW-501516, GW 501516, endurobol | Names vary in research and anti-doping documents. |
| Chemical class | Synthetic PPARδ agonist | Small-molecule nuclear receptor ligand. |
| CAS Registry Number | 317318-70-0 | Identifier commonly associated with GW501516. |
| Appearance | White to off-white powder | Typical for purified research material. |
| Solubility | Low in water; soluble in DMSO and ethanol | Organic solvents are common for laboratory stock solutions. |
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Outside the cell, LTC4 can be converted by ubiquitous enzymes to form successively LTD4 and LTE4, which retain biological activity. The cysteinyl-leukotrienes act at their cell-surface receptors CysLT1 and CysLT2 on target cells to contract bronchial and vascular smooth muscle, to increase permeability of small blood vessels, to enhance secretion of mucus in the airway and gut, and to recruit leukocytes to sites of inflammation. Both LTB4 and the cysteinyl-leukotrienes (LTC4, LTD4, LTE4) are partly degraded in local tissues, and ultimately become inactive metabolites in the liver.
=== Central nervous system and appetite regulation === Semaglutide crosses the blood-brain barrier to interact with the arcuate nucleus of the hypothalamus, a crucial brain region for energy balance. It suppresses appetite through a dual mechanism involving hypothalamic feeding circuits. Acute administration has been shown to stimulate anorexigenic (satiety-inducing) neurons that express proopiomelanocortin (POMC) and cocaine-and amphetamine-regulated transcript (CART), while simultaneously inhibiting orexigenic (appetite-inducing) neurons that express AgRP and NPY. However, more recent evidence indicates that during chronic treatment, AgRP neurons become functionally recruited and are required for the full weight-lowering effects of GLP-1 receptor agonists in female mice, despite persistent suppression of food intake. This recruitment is associated with increased neuronal activation, synaptic remodeling, and fat utilization, suggesting that AgRP neurons contribute to the adaptive metabolic responses that sustain long-term weight loss rather than simply promoting hunger. Furthermore, semaglutide improves the brain's sensitivity to leptin, a hormone produced by fat cells that signals satiety to the brain. In individuals with obesity, chronic low-grade inflammation often leads to "leptin resistance"—a pathological state where circulating leptin levels are high, but the brain fails to register the signal, leading to persistent hunger. Semaglutide counteracts this resistance by downregulating inhibitory proteins like SOCS3 and PTP1B.
==== Practical uses of polarised T-cell help ==== Polarisation in T-cell help is useful in influencing allergic responses and autoimmune diseases. In autoimmune diseases, the goal is to shift the self-destructive TH1 response (with its associated cytotoxic T cell activity) to a non-destructive TH2 response. This has been successfully applied in predisease priming for the desired type of response in preclinical models and is somewhat successful in shifting the response for an established disease.
[collagen]-(5R)-5-O-[α-D-glucosyl-(1→2)-β-D-galactosyl]-5-hydroxy-L-lysine + H2O = D-glucose + [collagen]-(5R)-5-O-(β-D-galactosyl)-5-hydroxy-L-lysine It belongs to the family of hydrolases, specifically those glycosidases that hydrolyse O- and S-glycosyl compounds. The systematic name is protein-α-D-glucosyl-1,2-β-D-galactosyl-L-hydroxylysine glucohydrolase. Other names in common use include 2-O-α-D-glucopyranosyl-5-O-α-D-galactopyranosylhydroxy-L-lysine glucohydrolase, and lysine glucohydrolase.
Sources: en.wikipedia.org
== Further reading == Hall E, Wodi AP, Hamborsky J, Morelli V, Schillie S, eds. (2021). "Chapter 20: Rubella". Epidemiology and Prevention of Vaccine-Preventable Diseases (14th ed.). Washington D.C.: U.S. Centers for Disease Control and Prevention (CDC).
=== Producing sulfuric acid from sulfur === A method of producing oleum sulphuris per campanam, or "oil of sulfur by the bell", was known by the 16th century: it involved burning sulfur under a glass bell in moist weather (or, later, under a moistened bell). However, it was very inefficient (according to Gesner, 5 pounds (2.3 kg) of sulfur converted into less than 1 ounce (0.03 kg) of acid), and the resulting product was contaminated by sulfurous acid (or rather, solution of sulfur dioxide) so most alchemists (including Isaac Newton) did not consider it equivalent to "oil of vitriol". In the 17th century, Johann Rudolf Glauber discovered that adding saltpeter (potassium nitrate, KNO3) and replacing moisture with steam significantly improves the output. As saltpeter decomposes, it oxidizes the sulfur to SO3, which combines with water to produce sulfuric acid. In 1736, Joshua Ward, a London pharmacist, used this method to begin the first large-scale production of sulfuric acid.
A range of algal morphologies is exhibited, and convergence of features in unrelated groups is common. The only groups to exhibit three-dimensional multicellular thalli are the reds and browns, and some chlorophytes. Apical growth is constrained to subsets of these groups: the florideophyte reds, various browns, and the charophytes. The form of charophytes is quite different from those of reds and browns, because they have distinct nodes, separated by internode 'stems'; whorls of branches reminiscent of the horsetails occur at the nodes. Conceptacles are another polyphyletic trait; they appear in the coralline algae and the Hildenbrandiales, as well as the browns. Most of the simpler algae are unicellular flagellates or amoeboids, but colonial and nonmotile forms have developed independently among several of the groups. Some of the more common organizational levels, more than one of which may occur in the lifecycle of a species, are
The green neon tetra (P. simulans) and black neon tetra (Hyphessobrycon herbertaxelrodi) are distinct species—the latter belongs to a different genus—and not color varieties. The cardinal tetra (P. axelrodi) is also a similar species, but its greater extent of red coloring distinguishes it from the neon tetra. The name Hyphessobrycon innesi is an obsolete synonym for P. innesi.
Nanohedron.com images of nanoparticles Lectures on All Phases of Nanoparticle Science and Technology Archived 29 August 2010 at the Wayback Machine ENPRA – Risk Assessment of Engineered NanoParticles EC FP7 Project led by the Institute of Occupational Medicine
Sources: en.wikipedia.org
Several yeasts, in particular S. cerevisiae and S. pombe, have been widely used in genetics and cell biology, largely because they are simple eukaryotic cells, serving as a model for all eukaryotes, including humans, for the study of fundamental cellular processes such as the cell cycle, DNA replication, recombination, cell division, and metabolism. Also, yeasts are easily manipulated and cultured in the laboratory, which has allowed for the development of powerful standard techniques, such as yeast two-hybrid, synthetic genetic array analysis, and tetrad analysis. Many proteins important in human biology were first discovered by studying their homologues in yeast; these proteins include cell cycle proteins, signaling proteins, and protein-processing enzymes. On 24 April 1996, S. cerevisiae was announced to be the first eukaryote to have its genome, consisting of 12 million base pairs, fully sequenced as part of the Genome Project. At the time, it was the most complex organism to have its full genome sequenced, and the work of seven years and the involvement of more than 100 laboratories to accomplish. The second yeast species to have its genome sequenced was Schizosaccharomyces pombe, which was completed in 2002. It was the sixth eukaryotic genome sequenced and consists of 13.8 million base pairs. As of 2014, over 50 yeast species have had their genomes sequenced and published. Genomic and functional gene annotation of the two major yeast models can be accessed via their respective model organism databases: SGD and PomBase.
=== Transformation in the environment === The silver nanoparticles that pass through wastewater treatment plants undergo transformations in the environment through changes in aggregation state, oxidation state, precipitation of secondary phases, or sorption of organic species. These transformations can result in the formation of colloidal solutions. Each of these new species potentially have toxic effects which have yet to be fully examined. Most silver nanoparticles in products have an organic shell structure around a core of Ag0. This shell is often created with carboxylic acids functional groups, usually using citrate, leading to stabilization through adsorption or covalent attachment of organic compounds. In seawater, glutathione reacts with citrate to form a thioester via esterification.
=== Marvel Studios' Infinity Saga Concert Experience === In May 2024, Marvel Studios' Infinity Saga Concert Experience was announced by Disney Concerts, Marvel Studios, and the Los Angeles Philharmonic, to premiere on August 30 and 31, 2024, at the Hollywood Bowl. The concert, conducted by the Philharmonic's Music and Artistic director Gustavo Dudamel, features the Philharmonic performing a "specially created score" of music from the Infinity Saga films, such as The Avengers theme and "Portals" from Avengers: Endgame, live to picture. The first half of the concert focused on individual characters from the films, while the second half centered on Avengers: Infinity War and Avengers: Endgame. A "post-credits scene" saw the Philharmonic play Michael Giacchino's theme from The Fantastic Four: First Steps (2025). The performance also used projection mapping on the proscenium of the Hollywood Bowl while audience members wore PixMob light-up wrist bands. The concert was set to go on tour globally in 2025.
== Nuclear properties == Technetium-99m is a metastable nuclear isomer, as indicated by the "m" after its mass number 99. This means it is a nuclide in an excited (metastable) state that lasts much longer than is typical. The nucleus will eventually relax (i.e., de-excite) to its ground state through the emission of gamma rays or internal conversion electrons. These decays do not change the number of protons or neutrons, but only give them a lower-energy 'arrangement', which here is the ground state. The excitation energy above the ground state is 142.7 keV, but 99% of the time, it relaxes first to a slightly lower state (140.5 keV) by internal conversion (and the rate of this transition determines the uncertainty in half-life), which decays at once. In total, 99mTc decays about 89% by gamma emission (99mTc → 99Tc + γ) and almost all of the time, this results in a 140.5 keV gamma ray and only rarely in a 142.7 keV (1 in 4,000) as the latter decay, too, is very largely converted. The remaining 11% of decays are completed entirely by conversion and not of diagnostic utility, though still contributing to internal radiation dose. These gammas are the radiations that are picked up by a gamma camera when 99mTc is used as a radioactive tracer for medical imaging. Pure gamma emission is the desirable decay mode for medical imaging because other particles deposit more energy in the patient body (radiation dose) relatively to that in the camera. Metastable isomeric transition is the only nuclear decay mode that approaches pure gamma emission.
=== By mouth === The basic appeal of hypoglycemic agents by mouth is that most people would prefer a pill or an oral liquid to an injection. However, insulin is a peptide hormone, which is digested in the stomach and gut and in order to be effective at controlling blood sugar, cannot be taken orally in its current form. The potential market for an oral form of insulin is assumed to be enormous, thus many laboratories have attempted to devise ways of moving enough intact insulin from the gut to the portal vein to have a measurable effect on blood sugar. A number of derivatization and formulation strategies are currently being pursued to in an attempt to develop an orally available insulin. Many of these approaches employ nanoparticle delivery systems and several are being tested in clinical trials.
Sources: en.wikipedia.org
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.
No. Cardarine is not a steroid hormone; it targets the nuclear receptor PPARδ. Its classification in anti-doping rules differs from anabolic steroids, though it remains prohibited in sport.
Early rodent studies reported tumor formation at multiple sites, which raised safety concerns. Sponsors stopped clinical development, and no approved human product exists.
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.